目的:探讨匹多莫德对老年支气管肺炎患者的疗效及对免疫功能的影响。方法:85例老年支气管肺炎患者随机分为匹多莫德治疗组43例和常规治疗组42例。常规治疗组给予莫西沙星400 mg·d-1ivd,匹多莫德治疗组在常规治疗基础上加用匹多莫德口服液800 mg,po,bid,两组均连续用药10 d,观察两组患者治疗前后免疫功能的变化及发热、咳嗽、气喘、啰音、肺部X线阴影发生率和症状持续时间。结果:两组患者治疗后的CD4、CD4/CD8和NK细胞均较治疗前显著升高,CD8细胞表达和Ig A、Ig G、Ig M表达水平均明显降低(P<0.05);且匹多莫德治疗组患者治疗前后变化更优于常规治疗组(P<0.05)。匹多莫德治疗组治疗后发热、咳嗽、气喘、啰音和肺部X线阴影发生率均显著低于常规治疗组(P<0.01),且各症状持续时间均显著低于常规治疗组(P<0.01)。结论:匹多莫德能有效治疗老年支气管肺炎的机制,与改善患者T细胞亚群及NK细胞以及体液免疫水平,提高机体免疫力相关。 Objective: To investigate the effect of pidotimod on elderly patients with bronchopneumonia and its effect on immune function. Methods: Eighty-five elderly patients with bronchial pneumonia were randomly divided into pidotimod-treated group (n = 43) and conventional treatment group (n = 42). The conventional treatment group was given moxifloxacin 400 mg · d-1ivd, Pidotimod treatment group on the basis of conventional treatment with Pidmodoctone oral 800 mg, po, bid, two groups were continuous medication for 10 d, two Changes in immune function before and after treatment in the group of patients and fever, cough, asthma, aura, lung X-ray incidence and duration of symptoms. Results: After treatment, the CD4, CD4 / CD8 and NK cells in both groups were significantly increased compared with that before treatment, while the expression of CD8 and Ig A, Ig G and Ig M were significantly decreased (P <0.05) The changes in patients in the Modal treatment group were better than those in the conventional treatment group before and after treatment (P <0.05). The incidence of fever, cough, asthma, rales and pulmonary X-ray shadow in the Pidotimode treatment group were significantly lower than those in the conventional treatment group (P <0.01), and the duration of each symptom was significantly lower than that in the conventional treatment group P <0.01). Conclusion: Pidotimod can effectively treat the bronchial pneumonia in elderly patients, and improve the patient’s T cell subsets, NK cells and humoral immunity, improve immunity.